Evidence map›Paper›PMID 38931365›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Barbaloin Protects Pentylenetetrazol-Induced Cognitive Deficits in Rodents via Modulation of Neurotransmitters and Inhibition of Oxidative-Free-Radicals-Led Inflammation.

Ahmad Essam Altyar, Muhammad Afzal, Nehmat Ghaboura, Khalid Saad Alharbi, Sattam Khulaif Alenezi, Nadeem Sayyed, Imran Kazmi

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ahmad Essam AltyarDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, P.O. Box 80260, Jeddah 21589, Saudi Arabia.ORCID 0000-0001-6210-3628
Muhammad AfzalDepartment of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeedah 21442, Saudi Arabia.
Nehmat GhabouraDepartment of Pharmacy Practice, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeedah 21442, Saudi Arabia.
Khalid Saad AlharbiDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Al Qassim 51452, Saudi Arabia.
Sattam Khulaif AleneziDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Al Qassim 51452, Saudi Arabia.ORCID 0000-0002-4988-9838
Nadeem SayyedGlocal School of Pharmacy, Glocal University, Mirzapur-Pole, Saharanpur 247121, India.ORCID 0000-0003-0517-4934
Imran KazmiDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, P.O. Box. 80200, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-1881-5219

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpilepsy is defined by an excessive level of activity in the neurons and coordinated bursts of electrical activity, resulting in the occurrence of seizure episodes. The precise cause of epileptogenesis remains uncertain; nevertheless, the etiology of epilepsy may involve neuroinflammation, oxidative stress, and malfunction of the neurotransmitter system.

objectiveThe goal of this investigation was to assess barbaloin's protective properties with respect to pentylenetetrazol (PTZ)-)-induced cognitive deficits in rats via antioxidative, anti-inflammatory, and neurotransmitter-modulating effects.

methods

resultsThe treatment of rats with barbaloin resulted in behavior improvement and significant changes in the levels of

conclusionsThe ongoing study has gathered evidence indicating that the injection of barbaloin has resulted in significant improvements in cognitive performance in rats. This is achieved by inhibiting oxidative stress, enhancing the activity of natural antioxidant enzymes, reducing cytokine levels, and increasing the levels of neurotransmitters in the brain. These results were detected in comparison to a PTZ control and can be attributed to the potent anti-inflammatory and antioxidant capabilities of barbaloin, which could be linked to its neuroprotective properties. Barbaloin may potentially increase cognitive decline and boost neuronal survival by altering the expression of

Indexed as

barbaloincytokinesneuroprotectiveoxidative stresspentylenetetrazol kindling

Identifiers

PMID38931365
PMCPMC11206990

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.